Back to top
more

Fortress Biotech (FBIO)

(Delayed Data from NSDQ)

$1.81 USD

1.81
118,993

-0.04 (-2.16%)

Updated Aug 1, 2025 04:00 PM ET

Pre-Market: $1.78 -0.03 (-1.66%) 8:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

New Strong Sell Stocks for May 16th

by Zacks Equity Research

FBIO, AFCG and HRZN have been added to the Zacks Rank #5 (Strong Sell) List on May 16, 2025.

Zacks Equity Research

Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -9.09% and 27.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -413.95% and 99.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -25.93% and 3.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 47.62% and 10.44%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.41% and 34.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 67.09% and 12.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 44.70% and 0.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -4.17% and 29.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 6.45% and 221%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -7.75% and 4.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 26.09% and 40.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aveanna (AVAH) delivered earnings and revenue surprises of 40% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 20% and 1.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -10.53% and 23.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline

by Zacks Equity Research

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -2.04% and 64.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?